Systemic sclerosis & Raynaud's

Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course

Arthritis RheumatolPublished Case-control study

Authors' conclusion

These data suggest that five distinct scleroderma immune responses, alone or in combination, may be useful tools to stratify the risk of cancer for scleroderma patients.

Study context

Population
Scleroderma patients from the Johns Hopkins Scleroderma Center and the University of Pittsburgh Scleroderma Center
Participants
676 vs 687
Comparison
Scleroderma autoantibody profiles in SSc patients with cancer vs SSc controls without cancer
  • Casesn = 676
  • Controlsn = 687reference
Outcome
Association of distinct scleroderma autoantibodies with overall cancer at any time
Methodological detailstwo-centre, logistic regression adjusted for relevant covariates, random forest analysis
  • Two-centre
  • Logistic regression adjusted for relevant covariates
  • Random forest analysis

Main finding

As reported in the abstract

Overall cancer risk by autoantibody (adjusted)

Anti-POLR3, OR (95% CI 1.03-2.11), increased risk

1.47

Monospecific anti-Ro52, OR (95% CI 1.29-3.74), increased risk

2.19

Anticentromere, OR (95% CI 0.51-0.93), lower risk

0.69

Anti-U1RNP, OR (95% CI 0.43-0.93), lower risk

0.63

Observational data: associations, not effects.

Further findings

Cancer-associated scleroderma (cancer within 3 years of scleroderma onset) by autoantibody

Anti-POLR3, OR
2.28 (95% CI 1.33-3.91)
Monospecific anti-Ro52, OR
2.58 (95% CI 1.05-6.30)
Anticentromere, OR
0.39 (95% CI 0.20-0.74)
Anti-U1RNP, OR
0.32 (95% CI 0.11-0.93)

Autoantibody combinations

Anti-Ro52 plus anti-U1RNP or anti-Th/To associated with decreased cancer risk vs anti-Ro52 alone

Original publication

Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course. Arthritis Rheumatol. Published 27 November 2023. doi:10.1002/art.42663

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.